Clinical Trial

A Phase I Study of SHR-3836 in Patients With Multiple Myeloma

Name: A Phase I Study of SHR-3836 in Patients With Multiple Myeloma — clinical trial record (NCT07490613)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a Phase I, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of SHR-3836 in patients with multiple myeloma (MM).

Protocol Amendment History 1 change

critical Recruitment opened 2026-06-05

Trial Details

NCT Number	NCT07490613
Lead Sponsor	Shanghai Hengrui Pharmaceutical Co., Ltd.
Conditions	Multiple Myeloma
Enrollment	99 participants
Start Date	2026-06-02
Primary Completion	2028-04 (estimated)
Study Completion	2029-04 (estimated)
Updated on ClinicalTrials.gov	2026-06-04